Gastric cancer (GC) is the third leading cause of global cancer morbidity and mortality. One of the significant challenges in GC treatment is that most GC patients are diagnosed with advanced-stage disease due to the lack of suitable biomarkers. Recent studies have shown that microRNAs (miRNAs) can acts as a potential biomarker in GC diagnosis and prognosis. I performed a systematic review of published miRNA studies in GC, which includes the miRNA expression profiles between GC tissues and normal tissues and also miRNA studies to evaluate their potential value in the diagnosis and prognosis of GC. Among the studies, upregulation of miR-21, miR-106b, miR-25, miR-214, miR-18a, miR-191, and miR-93 and downregulation of miR-375, miR-148a, miR-92, miR-155, and miR-564 were observed in GC tissues. In evaluating of diagnosis value of miRNAs, the study was performed on a combined miRNA include miR-21, miR-93, miR-106a, and miR-106b indicated the panel of these miRNAs have the highest AUC 0.887 to discriminate GC patients from healthy. Also, miR-940 with a sensitivity of 81.25% and specificity of 98.57% may be used for diagnostic biomarkers for GC. Finally, the pooled prognostic result of miR-21 for hazard ratios (HR) was 1.260 (95% CI 0.370–4.330, P < 0.001), showing that miR-21 could predict poor survival in GC patients. This systematic review can confirm that we need to find a miRNA or a panel of miRNAs with high sensitivity and specificity for further exploration to investigate a better diagnostic or therapeutic tool for personalized management of GC patients.

胃癌 (GC) 是全球癌症发病率和死亡率的第三大原因。GC 治疗面临的重大挑战之一是，由于缺乏合适的生物标志物，大多数 GC 患者被诊断出患有晚期疾病。最近的研究表明，微小RNA（miRNA）可以作为胃癌诊断和预后的潜在生物标志物。我对已发表的 GC miRNA 研究进行了系统回顾，其中包括 GC 组织和正常组织之间的 miRNA 表达谱以及 miRNA 研究，以评估它们在 GC 诊断和预后中的潜在价值。在这些研究中，miR-21、miR-106b、miR-25、miR-214、miR-18a、miR-191和miR-93的上调和miR-375、miR-148a、miR-92、miR的下调-155 和 miR-564 在 GC 组织中观察到。在评估 miRNA 的诊断价值时，该研究是对包括 miR-21、miR-93、miR-106a 和 miR-106b 的组合 miRNA 进行的，表明这些 miRNA 的面板具有最高的 AUC 0.887，可将 GC 患者与健康人区分开来。此外，具有 81.25% 敏感性和 98.57% 特异性的 miR-940 可用于 GC 的诊断生物标志物。最后，miR-21 的风险比 (HR) 汇总预后结果为 1.260（95% CI 0.370–4.330，P  < 0.001)，表明 miR-21 可以预测 GC 患者的不良生存率。该系统评价可以证实，我们需要找到一个具有高灵敏度和特异性的 miRNA 或一组 miRNA，以进行进一步探索，以研究更好的诊断或治疗工具，以对 GC 患者进行个性化管理。